Matthew Kalnik
Founder and Chief Executive Officer at Antidote Therapeutics
Bethesda, Maryland, United States
Find your path to Matthew
29 people in our graph share verified history with Matthew — schools, employers, funds. One of them is your warm intro.
Lisa ShieldsunlockedMatthew: together at Columbia University - Graduate School of Journalism (1988–1989)
×10Matthew: together at Columbia University - Graduate School of Journalism
Matthew: together at Nabi Biopharmaceuticals
Founder and Chief Executive Officer at Antidote Therapeutics
Experience
- Antidote Therapeutics, Inc.Founder and CEOcurrent2014 — presentSykesville, Maryland, United States
- Hedgerow ConsultingPresidentcurrent2003 — presentBethesda, MD
- Nabi BiopharmaceuticalsSenior Vice President, Strategic Planning and Business Operations2007 — 2012Rockville, MD
- Daiichi Medical ResearchSr. Director, Development Technology2005 — 2006Montvale, NJ
- Genaissance PharmaceuticalsSenior Vice President, Business Development and Licensing2004 — 2005New Haven, CT
Skills & more
Business Strategy5Business Development10
From Matthew's professional profile.
Frequently asked questions
- Who is Matthew Kalnik?
- Founder and Chief Executive Officer at Antidote Therapeutics
- Where does Matthew Kalnik work?
- Matthew Kalnik is Founder and Chief Executive Officer at Antidote Therapeutics.
- Where did Matthew Kalnik go to school?
- Matthew Kalnik studied at The Research Institute at Scripps Clinic (Post-Doctoral Fellowship, Molecular Biology and Biophysics); Columbia University - Graduate School of Journalism (Ph. D., Biochemistry & Molecular Biophysics).
Same school
Also attended Columbia University - Graduate School of Journalism28
Coral Garnick DuckenContent Marketing Manager at Madrona Venture GroupAnna ShenMarketing at RaivenBhumika DExecutive Assistant at Jungle VenturesDr. Gali EinavAcademic Director | Alpha-Bet at Vetted AcceleratorStephanie SirotaPartner, Chief Business Officer at RTW Investments L.P.Lisa Gokongwei ChengGeneral Partner at Kaya Founders
+ 22 more
